Measuring brain health with portable MRI technology
Measuring Brain Health Using Low-Field Portable MRI
This study is testing a new way to measure brain health using portable MRI technology to see how it compares to traditional MRI scans for people with white matter changes in their brains.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Yale University Academic / other |
| Locations | 1 site (New Haven, Connecticut) |
| Trial ID | NCT06533631 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a new grading scale for White Matter Hyperintensity (WMH) and utilize automated segmentation to measure WMH volume using low-field MRI technology. Participants will undergo both portable low-field MRI and high-field 3T MRI scans to compare measurements and validate the new grading scale. The study will involve a single visit lasting approximately 2 hours, or two visits if necessary, to ensure participant comfort. An expert panel will refine the grading scale using the Delphi method, while advanced machine learning techniques will be employed for precise quantification of WMH volume.
Who should consider this trial
Good fit: Ideal candidates include individuals with at least one vascular risk factor such as hypertension, hyperlipidemia, or diabetes.
Not a fit: Patients with a history of stroke, dementia, cognitive impairment, or those with MRI contraindications will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable and accessible method for assessing brain health in patients with vascular risk factors.
How similar studies have performed: Other studies have shown success in using advanced imaging techniques for brain health assessment, but the specific application of low-field MRI for WMH measurement is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * One vascular risk factor, from the following: 1. Hypertension (defined as taking an antihypertensive medication) 2. Hyperlipidemia (defined as taking a statin or PCSK9 inhibitor) 3. Diabetes (defined as taking a medication to prevent hyperglycemia) Exclusion Criteria: * 1\. History of stroke * History of dementia or other cognitive impairment * Pacemaker or other MRI contraindications according to the American College of Radiology guidelines
Where this trial is running
New Haven, Connecticut
- Yale Magnetic Resonance Research Center (MRRC) at The Analyn Center (TAC) — New Haven, Connecticut, United States (Recruiting)
Study contacts
- Principal investigator: Adam H de Havenon, MD — Yale University
- Study coordinator: Adam H de Havenon, MD
- Email: adam.dehavenon@yale.edu
- Phone: 203-785-4085
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.